

# BioMedCore Inc.

## The Leading Venture Company on New Liposome Technology

BioMedCore Inc., a Japanese start-up company with proprietary Liposome Technology, provides a novel way to mass-produce the high-quality liposome products with a narrow size distribution, large encapsulation volume, high encapsulation efficiency and sterility under GMP condition.



Based on this technology, BioMedCore Inc. focuses its effort on development of Mannose Coated Liposome (MCL) as the cellular immunity adjuvant for cancer, allergy and infectious disease vaccines. MCL technology is supported by a comprehensive IP-portfolio (patent families including composition, formulation, production, and applications) and backed by a group of Japanese seed fund investors and the government.

BioMedCore Inc. now seeks business collaboration with pharmaceutical companies for co-development of cancer vaccines and/or out-licensing of the MCL platform technology. In-house priority lies within therapeutic cancer vaccines with an aid of *ex vivo* CTL assay for *in vitro* screening of potent antigenic peptides.

The MCL technology has wide application possibilities in particular:

- **Adjuvant;** MCL strongly induces antigen-specific CTL with various cancer antigens including MHC class 1 specific peptides. This is achieved with a small amount of antigen, less than 1/100 – 1/1,000 of typical dosage, which will result in considerable production cost savings. MCL is the first known adjuvant that induces only cellular immune response. This is particularly useful for therapeutic vaccines towards cancer, allergy and infectious diseases.
- ***Ex vivo* CTL Assay;** MCL is also used as an *in vitro* adjuvant for amplification of CTL level, which can be measured with high sensitivity in two weeks. MCL could be a handy tool to evaluate clinical potential of cancer vaccines.
- **Drug Delivery System;** MCL, having anti-cancer agents, actively targets macrophages and are taken up by macrophages via mannose-receptors. Macrophages then migrate to lymph nodes or inflammatory sites where various cancer cells metastasize. Macrophages discharge high concentration of anti-cancer agents to the cancer cells with an aid of thermal stress.

### Mannose Coated Liposome & its anti-cancer effect



The MCL-technology claims are supported by numerous publications and some recently published data showing its excellent Th1 cytokine response including highly elevated IL-12 release.

BioMedCore Inc. is providing antigen-encapsulated MCL to pharmaceutical companies for *in vitro* and *in vivo* evaluation of cancer antigen candidates under collaborative research and development agreement.

At the same time, it is seeking licensing partners and R/D alliances to speed-up development of a cancer vaccine candidate that has been developed by BioMedCore Inc. under collaboration with one of the leading medical schools.

Please, kindly contact us for additional information and discussion about business opportunities.

Please contact with : Yuichiro Satoh, D.V.M., President of BioMedCore Inc.

Tel: +81-45-342-5514 Fax: +81-45-342-5524. Skype name 'satouy'. E-mail: [satouy@bmc core.co.jp](mailto:satouy@bmc core.co.jp).